CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 179 filers reported holding CRISPR THERAPEUTICS AG in Q2 2018. The put-call ratio across all filers is 3.04 and the average weighting 0.7%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $340,101 | -20.5% | 6,297 | +0.4% | 0.00% | – |
Q1 2024 | $427,636 | +14.7% | 6,274 | +5.4% | 0.00% | – |
Q4 2023 | $372,783 | -96.5% | 5,955 | -97.4% | 0.00% | -100.0% |
Q3 2023 | $10,593,980 | -19.1% | 233,399 | +0.1% | 0.01% | -16.7% |
Q2 2023 | $13,091,735 | +24.1% | 233,198 | +0.0% | 0.01% | +20.0% |
Q1 2023 | $10,545,963 | -11.8% | 233,163 | -20.7% | 0.01% | -16.7% |
Q4 2022 | $11,953,986 | -38.2% | 294,071 | -0.6% | 0.01% | -45.5% |
Q3 2022 | $19,341,000 | +8.8% | 295,972 | +1.1% | 0.01% | +22.2% |
Q2 2022 | $17,784,000 | -3.3% | 292,646 | -0.1% | 0.01% | +28.6% |
Q1 2022 | $18,389,000 | -22.3% | 292,959 | -6.3% | 0.01% | -22.2% |
Q4 2021 | $23,681,000 | -33.7% | 312,503 | -2.1% | 0.01% | -30.8% |
Q3 2021 | $35,730,000 | -30.3% | 319,215 | +0.8% | 0.01% | -35.0% |
Q2 2021 | $51,268,000 | -49.3% | 316,690 | -61.8% | 0.02% | -51.2% |
Q1 2021 | $101,056,000 | -20.0% | 829,354 | +0.5% | 0.04% | -22.6% |
Q4 2020 | $126,325,000 | +67.5% | 825,062 | -8.5% | 0.05% | +43.2% |
Q3 2020 | $75,427,000 | -9.8% | 901,813 | +0.3% | 0.04% | -14.0% |
Q2 2020 | $83,629,000 | +345.2% | 899,521 | +103.1% | 0.04% | +230.8% |
Q1 2020 | $18,785,000 | -29.2% | 442,947 | +1.7% | 0.01% | -7.1% |
Q4 2019 | $26,533,000 | +52.4% | 435,644 | +2.6% | 0.01% | +55.6% |
Q3 2019 | $17,405,000 | -13.0% | 424,613 | 0.0% | 0.01% | -18.2% |
Q2 2019 | $20,000,000 | +31.9% | 424,613 | 0.0% | 0.01% | +37.5% |
Q1 2019 | $15,167,000 | +10.7% | 424,613 | -11.4% | 0.01% | 0.0% |
Q4 2018 | $13,696,000 | -35.6% | 479,363 | 0.0% | 0.01% | -27.3% |
Q3 2018 | $21,259,000 | -49.9% | 479,363 | -33.6% | 0.01% | -50.0% |
Q2 2018 | $42,412,000 | +30.4% | 721,783 | +1.4% | 0.02% | +37.5% |
Q1 2018 | $32,534,000 | +74.4% | 711,733 | -10.4% | 0.02% | +77.8% |
Q4 2017 | $18,656,000 | +43.1% | 794,533 | +8.9% | 0.01% | +50.0% |
Q3 2017 | $13,033,000 | +11.5% | 729,333 | 0.0% | 0.01% | 0.0% |
Q2 2017 | $11,684,000 | -25.8% | 729,333 | 0.0% | 0.01% | -25.0% |
Q1 2017 | $15,738,000 | +9.4% | 729,333 | 0.0% | 0.01% | +14.3% |
Q4 2016 | $14,389,000 | – | 729,333 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Versant Venture Management, LLC | 498,558 | $37,781,000 | 20.21% |
Ariose Capital Management Ltd | 37,900 | $2,872,000 | 6.78% |
EcoR1 Capital, LLC | 1,077,483 | $81,652,000 | 2.60% |
NEA Management Company, LLC | 1,590,002 | $120,490,000 | 2.44% |
ARK Investment Management | 9,087,868 | $688,679,000 | 2.08% |
NIA IMPACT ADVISORS, LLC | 62,609 | $3,876,000 | 2.06% |
Deuterium Capital Management, LLC | 18,000 | $1,364,000 | 2.02% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 108,200 | $8,192,000 | 1.82% |
PLUSTICK MANAGEMENT LLC | 50,000 | $3,789,000 | 1.76% |
Nikko Asset Management Americas, Inc. | 4,319,471 | $330,526,000 | 1.74% |